Abstract
Background: Anlotinib, an oral multi-targeted tyrosine kinase receptor inhibitor, monotherapy improves OS and PFS as a third-line treatment for stage IV NSCLC. Bevacizumab added to paclitaxel/carboplatin is a standard first-line therapy for advanced non-squamous NSCLC. Previous study has explored the efficacy and safety of anlotinib in combination with chemotherapy as first-line therapy in advanced NSCLC patients. This is the first trial evaluating the combination of chemotherapy and anlotinib in treatment-naïve advanced non-squamous NSCLC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
